The addition of ivosidenib (Tibsovo) to azacitidine led to a threefold survival improvement for newly diagnosed IDH1-mutant acute myeloid leukemia (AML) patients who were ineligible for intensive ...
New data details molecular characterization of clinical response in patients with IDH1-mutated, newly-diagnosed acute myeloid leukemia (AML) treated with TIBSOVO® (ivosidenib tablets) in combination ...
TIBSOVO is the first targeted therapy to show improved event-free survival and overall survival in combination with azacitidine compared to azacitidine monotherapy. Safety profile consistent with ...
Abbvie ($ABBV) announced an update on their ongoing clinical study. AbbVie recently completed a clinical study titled ...
With a trial win in certain acute myeloid leukemia (AML) patients, Servier’s cancer med Tibsovo is primed to break into front-line use as a combo treatment for patients who can't handle intensive ...
Please provide your email address to receive an email when new articles are posted on . The addition of ivosidenib to azacitidine improved outcomes for certain patients with acute myeloid leukemia, ...
New data details molecular characterization of clinical response in patients with IDH1-mutated, newly-diagnosed acute myeloid leukemia (AML) treated with TIBSOVO ® (ivosidenib tablets) in combination ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback